摘要
目的:探讨阿立哌唑、舒必利对精神分裂症患者生活质量的影响。方法:对70例精神分裂症患者随机分为两组,分别给予阿立哌唑和舒必利治疗。疗程3个月。用阳性症状与阴性症状量表(PANSS)评定精神症状,用世界卫生组织编制的生活质量量表(WHOQOL-100)评定生活质量。结果:治疗3个月后,阿立哌唑对精神分裂症阳性症状、阴性症状的改善和舒必利相似,两组间PANSS评分差异无显著性。阿立哌唑组WHOQOL-100各领域除精神支柱外均明显改善,在生活领域、心理领域、独立性领域、社会关系领域较舒必利有显著改善。结论:阿立哌唑组患者生活质量优于舒必利组。
Objective：To explore the influence on quality of llfe of patients with schizophrenia treated by afipiprazole or sulpifide. Method： Seventy schizophrenic patients were randomly divided into aripiprazole group （afipiprazole treatment） and sulpifide group （sulpifide treatment） for three months. The psychiatric symptoms were evaluated by positive and negative symptom scale （PANSS） and the quality of life was assessed by World Health Onganization quality of life questionnaire（WHOQOL-100）. Results： Aripiprazole was similar to sulpiride in the improvement on positive and negative symptoms in schizophrenia, with no significant difference in the score of PANSS between the two groups after three months treatment. Except item of psychic support, all items in WHOQOL- 100 had a significant improvement in patients of aripiprazole group. Compared with sulpifide group, patients in aripiprazole group had marked improvement on those fields such as life, psychology, independence and social relationship. Conclusion： The patients in afipiprazole group has a better quality of life than in sulpifide group.
出处
《临床精神医学杂志》
2008年第1期43-44,共2页
Journal of Clinical Psychiatry
